Internal Medicine, Medical Oncology · Philadelphia, PA
NPI
1285070490
Since 2013
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
3401 N Broad St
Philadelphia, PA, 19140
Phone (215) 707-4000
Groups this clinician bills Medicare through
Medicare paid, 2024
$32K
355 services
Medicare patients, 2024
148
Average age 75
Drug cost, 2024
$2.8M
465 prescriptions
Company payments, 2025
$19K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marcus Messmer was code 99214 (office e&m - established), 160 times for 95 patients. In total Marcus Messmer billed 355 services in 13 codes, and Medicare paid $32K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-07-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 160 | 95 | $70.55 | $11K |
| 99215 Office E&M - Established | Facility | 120 | 60 | $108.79 | $13K |
| 99205 Office E&M - New | Facility | 24 | 24 | $147.19 | $3,533 |
By year: 2022 $24K for 246 services; 2023 $30K for 338 services; 2024 $32K for 355 services.
Medicare prescription drug claims, 2024
In 2024, the drug Marcus Messmer prescribed most often to Medicare patients was Brukinsa (Zanubrutinib), with 94 prescriptions and refills. In total Marcus Messmer wrote 465 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Brukinsa Zanubrutinib | 94 | 94 | 13 | $1.3M |
| Prednisone Generic | 40 | 40 | 11 | $101 |
| Calquence Acalabrutinib Maleate | 33 | 33 | Under 11 | $497K |
| Ondansetron Hcl Generic | 32 | 32 | 16 | $200 |
| Allopurinol Generic | 30 | 30 | Under 11 | $129 |
| Olanzapine Generic | 29 | 29 | 11 | $270 |
| Acyclovir Generic | 26 | 26 | Under 11 | $577 |
| Tazverik Tazemetostat Hydrobromide | 17 | 17 | Under 11 | $330K |
| Venclexta Venetoclax | 16 | 16 | Under 11 | $232K |
| Mirtazapine Generic | 15 | 15 | Under 11 | $199 |
| Duloxetine Hcl Generic | 13 | 16 | Under 11 | $95.34 |
| Entecavir Generic | 12 | 12 | Under 11 | $2,279 |
Brand drugs: 190 claims; generic drugs: 275 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marcus Messmer $19K ($19K in general payments such as food, travel and fees) from 15 companies. The largest payer was Incyte Corporation with $15K.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 20 | $15K |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $2,981 |
| BeOne Medicines USA, Inc. ONC | 1 | $149 |
| Daiichi Sankyo Inc. 4568.T | 6 | $142 |
| Genentech USA, Inc. ROG.SW | 2 | $102 |
| Pharmacosmos Therapeutics Inc. | 2 | $38.55 |
| Adc Therapeutics America, Inc. | 1 | $36.66 |
| Regeneron Pharmaceuticals, Inc. REGN | 1 | $28.97 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $27.03 |
| Celgene Corporation BMY | 1 | $26.27 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.